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Abstract
Background: Methicillin-Resistant Staphylococcus aureus (MRSA) has become a leading cause of pneumonia
in the United States and there is limited data on treatment outcomes in obese patients.We evaluated the effectiveness
of linezolid compared to vancomycin for the treatment of MRSA pneumonia in a national cohort of obese Veterans.
Methods: This retrospective cohort study included obese patients (body mass index ≥ 30) admitted to Veterans
Affairs hospitals with MRSA-positive respiratory cultures and clinical signs of infection between 2002 and 2012.
Patients initiating treatment with either vancomycin or linezolid, but not both, were selected for inclusion. Propensity
matching and adjustment of Cox proportional hazards regression models quantified the effect of linezolid compared
with vancomycin on time to hospital discharge, intensive care unit discharge, 30-day mortality, inpatient mortality,
therapy discontinuation, therapy change, 30-day readmission, and 30-day MRSA reinfection. We performed
sensitivity analyses by vancomycin Minimum Inhibitory Concentrations (MICs) and true trough levels.
Results: We identified 101 linezolid and 2,565 vancomycin patients. Balance in baseline characteristics
between the treatment groups was achieved within propensity score quintiles and between propensity matched pairs
(76 pairs). No significant differences were observed for the outcomes assessed. Among patients with vancomycin
MICs of ≤ 1 μg/mL, the linezolid group had a significantly lower mortality rate, increased length of hospital stay,
and longer therapy duration. There were no differences between the linezolid and vancomycin MICs of ≥ 1.5 μg/
mL groups. Clinical outcomes among those with vancomycin trough concentrations of 15-20 mg/L were similar to
patients treated with linezolid.
Conclusions: In our real-world comparative effectiveness study among obese patients with suspected MRSA
pneumonia, linezolid was associated with a significantly lower mortality rate as compared to the vancomycin-treated
patients with lower vancomycin MICs. Further studies are needed to determine whether this beneficial effect is
observed in other study populations.
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Abbreviations: BAL: Bronchoalveolar Lavage; BMI: Body
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Introduction
Methicillin-Resistant Staphylococcus aureus (MRSA) is one of
the most prevalent, pathogenic antimicrobial-resistant organisms,
causing invasive infections worldwide [1]. MRSA has become a leading
cause of pneumonia in both healthcare and community settings [2,3].
Furthermore, approximately 69% of adults in the United States (US)
are either overweight or obese [4], which is concerning as obesity is an
independent risk factor for developing pneumonia [5,6].
Limited treatment options exist for patients with MRSA
pneumonia, and for many years, vancomycin, a glycopeptide
antibiotic that inhibits Gram-positive bacterial cell wall synthesis by
binding a D-alanyl-D-alanine cell wall precursor that is essential for
peptidoglycan cross-linking, has served as the standard of care [7-9].
However, over time, clinical outcomes among vancomycin-treated
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patients with MRSA pneumonia have worsened [10]. In addition, the
use of the vancomycin in MRSA pneumonia has been questioned due
to poor penetration into alveolar fluid and the emergence of bacteria
with decreased vancomycin susceptibility [2,7,10]. These limitations
have prompted the need for additional therapeutic options. Linezolid,
an oxazolidinone antibiotic that inhibits protein synthesis at the 50S
ribosome, is recommended for the treatment of pneumonia caused by
Staphylococcus aureus (methicillin-susceptible and resistant strains)
bacteria [11]. While linezolid has been shown to achieve high lung
concentrations, there is limited evidence to support clinical superiority
over vancomycin [10,12-15]. Moreover, the optimal treatment in obese
patients is largely unknown.
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Obesity is associated with an increased risk of pneumonia [5,6].
Decreased immunity, a higher risk of aspiration, reduced lung volume,
and an altered ventilation pattern, impact pneumonia risk in obese
patients [5,6]. Furthermore, obesity itself is an independent predictor
of antibiotic treatment failure [16]. To date, there is no published
research comparing linezolid and vancomycin in obese patients
with MRSA pneumonia in the real-world clinical setting. Due to the
increasing complexity of treating MRSA pneumonia, controversial
superiority data, and the scarcity of data in the obese, we sought to
evaluate the effectiveness of linezolid therapy compared to vancomycin
for the treatment of suspected MRSA pneumonia in a national cohort
of obese Veterans.

Materials and Methods
Data sources
The Veterans Health Administration has utilized an electronic
medical record system since 1999 [17]. Our study included national
standardized databases capturing patient care including International
Classification of Diseases, 9th Revision, Clinical Modification (ICD-9CM) diagnostic and procedure codes, microbiology results, pharmacy
records for prescriptions and barcode administration, laboratory
results, vital status, and vital signs.

Study population
We conducted a national retrospective cohort study quantifying
the effectiveness of linezolid compared to vancomycin among obese
patients with suspected MRSA pneumonia. We identified hospital
in patients with positive MRSA cultures from a pulmonary site
between January 1, 2002 and December 1, 2012. Patients exposed
to at least 1 day of therapy with linezolid (intravenous or oral) or
vancomycin (intravenous only) were selected for inclusion. Next we
identified all obese patients with a body mass index (BMI) ≥ 30 [18].
BMI calculations were based on the most recent height and weight
measurements within a year of treatment initiation. Additionally, we
included patients initiating linezolid or vancomycin therapy within a
window of 3 days prior to culture through 4 days after culture with
an absence of linezolid or vancomycin therapy in the 7 days prior to
treatment initiation.
Of the patients with culture-positive MRSA treated with either
linezolid or vancomycin, an additional inclusion criterion included
clinical signs of infection based on the presence of a chest x-ray, or a
fever, or an elevated white blood cell count [3,19]. Each clinical sign
was assessed between the admission date and treatment initiation date.
Fever was defined as a temperature ≥ 100.4⁰F. An elevated white blood
cell count was defined as ≥10,000/mm3. We excluded patients who died
or were discharged within 2 days of treatment initiation and patients
exposed to more than 2 consecutive days of other antibiotic therapy
with activity against MRSA (clindamycin, daptomycin, doxycycline,
linezolid, minocycline, tigecycline, trimethoprim/sulfamethoxazole,
vancomycin) in the 3 days prior to or during treatment with linezolid
or vancomycin. Only the first admission within the study period
meeting all inclusion and exclusion criteria was included. The purpose
of the exclusion criteria were three-fold, to identify patients: (1) with
clinical signs of infection in addition to a positive culture, (2) who were
still in the hospital the day after treatment initiation, and (3) treated
with monotherapy.

Outcomes
The primary outcome of interest was time to hospital discharge.
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Therapy initiation was used to define the index date of treatment.
Time calculations were made from the index date to the event date
for each endpoint. The secondary endpoints of interest included
time to Intensive Care Unit (ICU) discharge, 30-day mortality,
inpatient mortality, therapy discontinuation, therapy change, 30-day
readmission, and 30-day MRSA reinfection. For hospital discharge,
patients who died during the admission were censored on their date of
death. Transfer out of an ICU was assessed among patients initiating
linezolid or vancomycin therapy in the ICU.
Antimicrobial drug exposures with activity against MRSA were
assessed for each patient during the admission. These exposures
were classified into dichotomous variables based on the class of the
antimicrobial agent and by the duration of receipt of agents in each
class. Therapy change was defined as discontinuation of linezolid
or vancomycin and initiation of another agent with anti-MRSA
activity. As such, therapy change could have included switching from
linezolid to vancomycin, switching from vancomycin to linezolid, or
switching from either linezolid or vancomycin to another anti-MRSA
antibiotic (listed above). Switching an antibiotic (i.e. linezolid) from
an intravenous to an oral route was not considered a therapy change.
Clinical rationale for therapy change, such as de-escalation resulting
from clinical improvement or change in therapy as a result of failure
was not ascertained. For 30-day readmission to a VA medical unit
and 30-day MRSA reinfection, patients who died after discharge were
censored on their date of death. The end of the follow-up period was
December 31, 2012.

Statistical analysis
To assess baseline differences between the two study groups, we
utilized a Fisher’s exact or χ2 test for categorical data. For continuous
variables of interest, we used a t-test for normally distributed data and
the non-parametric Wilcoxon Rank Sum test was used otherwise. We
employed propensity score methods, where the predicted probability
of treatment with linezolid was derived from an unconditional logistic
regression model using a manual backward, non–computer-generated,
elimination approach [20-22]. Propensity score stratification and
matching within propensity score calipers were implemented, related
assumptions were assessed, and subsequent covariate balance was
reviewed [20,21].
In the second stage of modeling, we used Cox proportional hazards
regression models to quantify the effect of linezolid treatment in obese
patients with MRSA pneumonia compared to vancomycin on the
aforementioned outcomes. We further evaluated Cox proportional
hazards model assumptions, including that of proportionality, with
formal tests and graphical displays [23]. If the confidence interval of
the hazard ratio included one, then the clinical outcome occurred
at comparable rates in both the linezolid and vancomycin groups.
A hazard ratio greater than one indicated an increased probability
of the event occurring sooner in the linezolid group compared to
the reference vancomycin group. In terms of the study outcomes, a
hazard ratio greater than one would represent a higher mortality rate,
decreased length of stay, or a higher readmission rate among patients
treated with linezolid. Alternatively, a hazard ratio less than one would
mean time to mortality was lower and length of stay was higher in the
linezolid group as compared to vancomycin.
We conducted subgroup analyses among patients with morbid
obesity (BMI ≥ 40) and with positive Bronchoalveolar Lavage (BAL)
cultures. Additionally, we assessed the study outcomes among a
restricted study population of those with a pneumonia-related diagnosis
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code present during the hospital admission (ICD-9-CM codes 003.22,
020.3, 020.4, 020.5, 021.2, 022.1, 031.0, 039.1, 052.1, 055.1, 073.0, 083.0,
112.4, 114.0, 114.4, 114.5, 115.05, 115.15, 115.95, 130.4, 136.3, 480-486,
513.0, 517.1) [24].
We also performed several sensitivity analyses. First, we assessed
linezolid effectiveness as compared to patients with vancomycin
minimum inhibitory concentrations (MICs) of ≤ 1 μg/mL and those
with vancomycin MICs of ≥ 1.5 μg/mL. Second, we assessed linezolid
effectiveness as compared to patients with true vancomycin trough
concentrations of 15-20 mg/L and no evidence of acute kidney injury
(defined as an increase in serum creatinine of 0.3 mg/dL or 50% prior
to starting vancomycin) [25]. True vancomycin troughs were defined
as levels obtained at steady state, with at least 3 vancomycin doses
before the level, that were taken less than 2 hours before the next
vancomycin dose or within 2 hours of the average interval between
the two prior vancomycin doses [25]. Only the first trough level after
the third vancomycin dose which met our steady state definition was
assessed. We did not assess change in vancomycin dosing based on
trough results. All analyses were performed using SAS (SAS Institute
Inc., Cary, NC,Version 9.3).

Results
We identified 2,666 obese patients with suspected MRSA
pneumonia who met our inclusion and exclusion criteria (Figure 1).
There were 2,565 (96.2%) patients in the vancomycin group and 101
(3.8%) in the linezolid group. Among those treated with linezolid,
approximately 91% (n=92) were dosed twice daily. The mean patient
age at the time of culture collection was 66 years for linezolid and
68 years for vancomycin (Table 1). Several statistically significant
differences in the frequency of current comorbidities, present during
the suspected MRSA pneumonia admission, were observed, including
chronic ulcer, dialysis, rheumatoid arthritis, and cerebrovascular
disease. Medical histories in the year prior to the suspected MRSA
pneumonia hospitalization, including pneumonia, osteomyelitis, and
allergy to vancomycin, differed significantly between the treatment
groups. Patients in the linezolid group had higher utilization of linezolid
in the 90 days prior to the suspected MRSA pneumonia hospitalization
(Table 2). Furthermore, surgical procedures in the previous 90 days
and MRSA bronchial culture sites were more common in the linezolid
group compared to the vancomycin group.
Though differences in baseline variables were observed between
the treatment groups, balance was achieved within propensity score
quintiles and between propensity matched pairs (linezolid=76,
vancomycin=76). In propensity score quintile adjustment, quintile I
served as the reference. Propensity score matching was achieved within
0.001 caliper. The propensity score model can be found in the footnote
of Table 3. This model demonstrated excellent discrimination between
the treatment groups (C-statistic 0.84) [22].
The median time to discharge was 15 days (interquartile range
[IQR] 7-30) among linezolid-treated patients versus 12 days (IQR 7-23)
in vancomycin-treated patients. Time to discharge was significantly
longer in the linezolid group compared to the vancomycin group in the
unadjusted analysis (hazard ratio [HR] 0.76, 95% confidence interval
[CI] 0.60-0.96) and non-significantly longer in propensity adjusted (HR
0.85, 95% CI 0.66-1.08) and propensity matched analyses (HR 0.96,
95% CI 0.56-1.65; Table 3). The inpatient mortality (28%) and 30-day
mortality (28%) rates were high but similar between treatment groups
among this obese cohort with positive MRSA pulmonary cultures.
No significant differences were observed in unadjusted, adjusted, or
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matched Cox proportional hazards models for time to ICU discharge,
30-day mortality, inpatient mortality, therapy discontinuation, therapy
change, 30-day MRSA pneumonia reinfection, or 30-day readmission.
Results similar to the overall cohort were observed in subgroup
analyses among morbidly obese patients (BMI ≥ 40; linezolid n=29,
vancomycin n=562) and those with positive BAL cultures (linezolid
n=13, vancomycin n=165). Time to hospital discharge in the morbidly
obese was significantly longer in the linezolid group in the unadjusted
(HR 0.50, 95% CI 0.32-0.79) and propensity adjusted (HR 0.51, 95%
CI 0.32-0.81) analyses and non-significant in propensity matched
analyses (HR 0.50, 95% CI 0.15-1.66). No significant differences were
observed for the other outcomes or by BAL subgroup. Regarding the
subgroup analysis among patients with a pneumonia diagnosis code
(linezolid n=67, vancomycin n=1,612), patients treated with linezolid
demonstrated a significantly lower rate of therapy discontinuation
(propensity matched HR 0.42, 95% CI 0.20-0.87) compared to patients
treated with vancomycin, indicating length of therapy was longer in the
vancomycin group.
Among the vancomycin group, we identified 984 eligible patients
(38%) for the sensitivity analyses evaluating effectiveness by vancomycin
MICs. Of them, 85% (n=833) had vancomycin MICs ≤ 1 μg/mL, 1%
(n=10) had a MIC=1.5 μg/mL, 14% (n=141) had a MIC=2 μg/mL,
and no patients had MICs > 2 μg/mL. Patients on linezolid showed
significantly lower rates of 30-day mortality (Table 4; propensity
matched HR 0.35, 95% CI 0.14-0.90) and therapy discontinuation
(propensity matched HR 0.49, 95% CI 0.27-0.87) than those with
vancomycin MICs of ≤ 1 μg/mL, meaning linezolid patients had longer
survival in the 30 days after discharge and a longer duration of therapy
than vancomycin patients with MICs of ≤ 1 μg/mL. Time to hospital
discharge was significantly longer in the linezolid group compared to
the vancomycin group with MICs of ≤ 1 μg/mL (unadjusted HR 0.69,
95% CI 0.54-0.89; propensity adjusted HR 0.72, 95% CI 0.55-0.93; and
propensity matched HR 0.52, 95% CI 0.29-0.93).
Only 12% (n=301) of vancomycin patients had accurately obtained
through concentrations without evidence of acute kidney injury. In
sensitivity analyses among these patients with vancomycin trough
levels obtained at steady state, 19% (n=58) had therapeutic trough
concentrations less than 10 mg/L, 29% (n=86) had 10-15 mg/L, 22%
(n=66) had 15-20 mg/L, and 30% (n=91) had greater than or equal
to 20 mg/L. All clinical outcomes were similar among linezolid
patients as compared to vancomycin patients with vancomycin trough
concentrations between 15-20 mg/L.

Discussion
To our knowledge, this is the first real-world comparative
effectiveness study assessing linezolid and vancomycin for the treatment
of suspected MRSA pneumonia in obese patients. Rates of hospital
discharge, ICU discharge, 30-day mortality, inpatient mortality,
therapy discontinuation, therapy change, 30-day MRSA pneumonia
reinfection, and 30-day readmission did not differ significantly between
linezolid and vancomycin in our study.
Our results agree with a recently published analysis of two linezolid
clinical trials in which clinical success and microbiologic success were
similar across all quartiles of weight in patients with nosocomial MRSA
pneumonia [26]. This appears to be the only other study evaluating
clinical outcomes among obese MRSA pneumonia patients treated with
linezolid or vancomycin. Additionally, our findings are consistent with
previous research comparing linezolid and vancomycin in non-obese
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Adult (≥18 years) inpatients with positive MRSA cultures from
pulmonary sites between 2002-2012
N=28,692

Excluded

• No treatment initiation with
linezolid or vancomycin in 3 days
prior to culture or 4 days after
culture (N=10,597)

At least one record of linezolid or vancomycin within an 8-day
window from culture date (-3 days to +4 days)
N=18,095

• BMI < 30 or BMI missing
(N=13,492)
Obese (BMI ≥ 30) patients

N=4,603

• History of linezolid or
vancomycin use in the 7 days
prior to treatment initiation
(N=1,199)

No history of linezolid or vancomycin use in the 7 days prior to
treatment initiation
N=3,404
• No clinical signs of infections
(N=175)
Clinical signs of infection based on the presence of a chest x3

ray, or a fever ≥ 100.4 F, or leukocytosis > 10,000/mm
N=3,229

• Death or discharge within 2 days
of treatment initiation (N=330)
• Combination therapy (N=233)
No death or discharge within 2 days of treatment initiation and
linezolid or vancomycin monotherapy
N=2,666

Linezolid
N=101

Vancomycin
N=2,565

MRSA: Methicillin-Resistant Staphylococcus; BMI: Body Mass Index
Figure 1: Study Cohort Identification
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Demographic characteristics

Linezolid
N=101

Vancomycin
N=2,565

P-value

Age (years)
Male

66.2 ± 12.3

67.6 ± 11.2

0.22

98 (97.0)

2,489 (97.0)

0.99

30-35

63 (62.4)

1,652 (64.4)

35-40

9 (8.9)

351 (13.7)

40+

29 (28.7)

562 (21.9)

Body mass index
0.15

Current comorbid conditions1)
Charlson score

3.7 ± 2.7

3.6 ± 2.5

0.84

Elixhauser score

4.7 ± 2.5

4.3 ± 2.0

0.18

Chronic renal disease

34 (33.7)

718 (28.0)

0.21

Peripheral vascular disease

9 (8.9)

236 (9.2)

0.92

Cancer

17 (16.8)

487 (19.0)

0.59

Cerebrovascular disease

6 (5.9)

363 (14.2)

0.02*

Congestive heart failure

43 (42.6)

1,031 (40.2)

0.63

Diabetes

53 (52.5)

1,196 (46.6)

0.25

Rheumatoid arthritis

5 (5.0)

27 (1.1)

< 0.001*

Hypertension

53 (52.5)

1,532 (59.7)

0.15

Hypothyroidism

10 (9.9)

148 (5.8)

0.08

Coagulopathy

6 (5.9)

233 (9.1)

0.28

Fluid and electolyte disorder

45 (44.6)

986 (38.4)

0.22

Depression

25 (24.8)

365 (14.2)

0.003*

Other neurological disorders

22 (21.8)

440 (17.2)

0.23

Bactremia

11 (10.9)

419 (16.3)

0.14

Skin/subcutaneous infection

32 (31.7)

638 (24.9)

0.12

Chronic ulcer

26 (25.7)

424 (16.5)

0.02*

Dialysis

18 (17.8)

285 (11.1)

0.04*

Pneumonia

67 (66.3)

1,612 (62.9)

0.48

Enterococcus

31 (30.7)

463 (18.1)

0.001*

VRE

20 (19.8)

218 (8.5)

< 0.001*

Psudomonas aeruginosa

31 (30.7)

508 (19.8)

0.008*

Blood

12 (11.9)

359 (14.0)

0.55

Bone

5 (5.0)

25 (1.0)

0.002*

Nares

< 5 (<5.0)

112 (4.4)

1.00

Skin

20 (19.8)

404 (15.8)

0.27

Urine

9 (8.9)

183 (7.1)

0.50
0.24

Culture-confirmed infections with

Concomitant2) MRSA infection site

Medical history3)
Previous Elixhauser score

5.4 ± 3.1

5.0 ± 3.0

Previous chronic renal disease

31 (30.7)

593 (23.1)

0.08

Previous diabetes

63 (62.4)

1,350 (52.6)

0.05*

Previous rheumatoid arthritis

5 (5.0)

56 (2.2)

0.07

44 (43.6)

903 (35.2)

0.09

Previous hypothyroidism

16 (15.8)

248 (9.7)

0.04

Previous bactremia

7 (6.9)

115 (4.5)

0.25

Previous osteomyelitis

8 (7.9)

74 (2.9)

0.004*

Previous surgery/medical care complication

13 (12.9)

234 (9.1)

0.20

Previous allergy to vancomycin

9 (8.9)

14 (0.6)

< 0.001*

Previous pneumonia

32 (31.7)

598 (23.3)

0.05*

Enterococcus

12 (11.9)

163 (6.4)

0.03*

VRE

6 (5.9)

48 (1.9)

0.004*

Previous congestive heart failure

Previous culture-confirmed infections with

Data are mean ± standard deviation or number (%) of patients. MRSA: Methicillin-Resistant Staphylococcus aureus; VRE: Vancomycin-Resistant Enterococcus
1. Present during the MRSA pneumonia hospitalization.
2. Present between the MRSA pneumonia admission and the end of treatment
3. Present in the 1 year prior to the admission with a positive MRSA pulmonary culture.
* p<0.05
Table 1: Demographics and Comorbid Conditions by Treatment Group
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Healthcare and antibiotic exposures

Linezolid
N=101

Vancomycin
N=2,565

P-value

0.44

Hospital unit at treatment initiation
Intensive care

39 (38.6)

895 (34.9)

General medicine / Other

62 (61.4)

1,669 (65.1)

Surgery during the current admission

46 (45.5)

1,039 (40.5)

0.31
0.01*

MRSA culture site
Bronchial

13 (12.9)

165 (6.4)

Non-bronchial (i.e. lung)

88 (87.1)

2,400 (93.6)

2002

5 (5.0)

112 (4.4)

2003

5 (5.0)

238 (9.3)

2004

10 (9.9)

271 (10.6)

2005

8 (7.9)

258 (10.1)

2006

5 (5.0)

247 (9.6)

2007

11 (10.9)

253 (9.9)

2008

16 (15.8)

253 (9.9)

2009

7 (6.9)

235 (9.2)

2010

16 (15.8)

234 (9.1)

2011

8 (7.9)

263 (10.2)

2012

10 (9.9)

201 (7.8)

Year

0.15

Region of facility
Northeast

14 (13.9)

434 (16.9)

South

53 (52.5)

1,198 (46.7)

Midwest

24 (23.8)

515 (20.1)
418 (16.3)

0.23

West

10 (9.9)

Length of therapy (days)

8.3 ± 5.3

7.3 ± 5.9

Previous hospitalization, 90 days

38 (37.6)

991 (38.6)

0.84

Previous surgery, any, 90 days

22 (21.8)

324 (12.6)

0.01*

Previous nursing home stay, 90 days

7 (6.9)

166 (6.5)

0.85

Number of antibiotics

1.6 ± 0.6

1.3 ± 0.5

< 0.001*

Number of days with antibiotic use

13.3 ± 11.6

8.2 ± 9.4

0.01*

Linezolid

10 (9.9)

22 (0.9)

<0.001*

Vancomycin

18 (17.8)

300 (11.7)

0.06

Other antibiotics

9 (8.9)

120 (4.7)

0.05*

0.08

Previous anti-MRSA antibiotic1)

Data are mean ± standard deviation or number (%) of patients. MRSA: Methicillin-Resistant Staphylococcus aureus.
1. Present in the 90 days prior to the admission with a positive MRSA pulmonary culture.
* p<0.05
Table 2: Healthcare and Antibiotic Exposures and Hospitalization-Related Characteristics by Treatment Group

patients [15,27-30]. Two meta-analyses which compared vancomycin
and linezolid for nosocomial pneumonia, found no differences in
clinical and microbiologic outcomes or mortality [29,30]. While
many trials have demonstrated equivalent efficacy between linezolid
and vancomycin [12,14], a recent prospective, randomized, doubleblind trial of MRSA pneumonia demonstrated higher clinical and
microbiologic success rates with linezolid over vancomycin, however
mortality was similar between the two groups [15]. Although several
studies have shown benefits for linezolid treatment compared with
vancomycin [10,15,31], their methodological and statistical limitations
have been frequently debated in the literature [32-34].
There is conflicting evidence surrounding treatment outcomes
with vancomycin at higher MICs. Some studies suggest patients with
MRSA infections are more likely to experience clinical success with
vancomycin if the vancomycin MIC is < 1 μg/mL as compared to
patients with higher MICs [35,36]. In an observational study of 158
patients with hospital-acquired, ventilator-associated or healthcareassociated MRSA pneumonia, mortality increased as a function of
Adv Pharmacoepidemiol Drug Saf
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the vancomycin MIC [37]. The overall all-cause 28-day mortality rate
in these patients was 32.3%, with the majority of isolates having a
vancomycin MIC ≥ 1.5 μg/mL (115/158, 72.8%) [37]. However, a recent
meta-analysis examining the association between vancomycin MIC
and mortality rates in patients with Staphylococcus aureus bacteremia
demonstrated no significant differences in mortality between patients
with lower-vancomycin MICs (< 1.5 μg/mL) and those with higherMICs (≥ 1.5 μg/mL) [38].
In our sensitivity analyses, we observed significant differences
between treatment groups when restricting the vancomycin group to
patients with lower MICs (≤ 1 μg/mL). Linezolid was associated with
a significantly lower discharge rate, representing an increased length
of stay, a significantly decreased rate of therapy discontinuation,
indicating longer therapy duration, and a significantly lower rate of
30-day mortality, representing greater survival, as compared to the
vancomycin group with MICs of ≤ 1 μg/Ml. We believe this is the
first study to demonstrate improved outcomes with linezolid in obese
patients, as compared to those receiving vancomycin and infected with
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HR: Hazard Ratio; CI: Confidence Interval; ICU: Intensive Care Unit; MRSA: Methicillin-Resistant Staphylococcus aureus.
1. Adjusted by propensity score quintiles (reference quintile I).
2. Propensity score matched within 0.001 caliper.
The propensity score was derived from an unconditional logistic regression model controlling for age, body mass index, Elixhauser score, time to therapy initiation
from culture date, year, region of facility, hospital unit at treatment initiation, culture site, history of MRSA infection, elevated white blood cell count, current diabetes
complications, current myocardial infarction, current cerebrovascular disease, current rheumatoid arthritis, current hypertension, current other neurological disorders,
current coagulopathy, current fluid and electolyte disorder, current depression, current skin infection, current chronic ulcer, current bacteremia, current immune disorder,
current dialysis, current VRE infection, current Psudomonas aeroginosa infection, concomitant MRSA infection in bone, history of chronic renal disease, history of diabetes,
history of cancer, history of congestive heart failure, history of hypothyroidism, history of burn, history of pneumonia, history of bacteremia, history of osteomyelitis, history
of neutropenia, history of VRE infection, history of allergy to vancomycin, nursing home stay in previous 30 days, surgery in previous 90 days, linezolid in previous 90 days,
trimethoprim/sulfamethoxazole in previous 90 days, daptomycin in previous 90 days, number of antibiotic used in previous 90 days (C-statistic 0.84).
Table 3: Outcomes in Overall Cohort: Linezolid Compared with Vancomycin
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HR: Hazard Ratio; CI: Confidence Interval; BMI: Body Mass Index; ICD-9-CM: International Classification of Diseases, 9th Revision, Clinical Modification; MIC: Minimum
Inhibitory Concentration.
1. Adjusted by propensity score quintiles (reference quintile I).
2. Propensity score matched within 0.001 caliper.
Table 4: Subgroup and Sensitivity Analyses: Linezolid Compared with Vancomycin

low MIC strains. On the contrary, there were no significant differences
in clinical outcomes between treatment groups when restricting the
vancomycin group to those with vancomycin MICs of ≥ 1.5 μg/mL.
Since this was a national study, MIC testing systems varied by facility
and MIC testing methodology was not specified in the data.
Appropriate dosing of antibiotics in obese patients is extremely
difficult and may result in underdosing [9,39]. Furthermore, 28% of our
cohort had a diagnosis of chronic renal disease during the admission,
which further complicates appropriate dosing in the obese population.
Obese patients treated with vancomycin may be less likely to achieve
optimal dosing, which puts patients at risk for poor outcomes [40],
even if they had a favorable vancomycin susceptibility.
Vancomycin trough concentrations of 15-20 mg/L are
recommended for severe infections, including MRSA pneumonia,
in order to improve penetration, increase the probability of optimal
serum vancomycin concentrations, and improve clinical outcomes
[25]. However the optimal trough in obese patients is largely unknown.
Among patients with true vancomycin trough concentrations, only 22%
(n=66) were in therapeutic range. All clinical outcomes were similar
in patients with vancomycin trough levels of 15-20 mg/L compared
to patients receiving linezolid. Although we found no significant
Adv Pharmacoepidemiol Drug Saf
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differences between linezolid and vancomycin, the relatively small
number of patients with true trough levels of 15-20 mg/L may have
affected our ability to detect differences between the treatment groups.
There is always the potential for observational studies to be
impacted by bias and residual confounding. To address these potential
limitations, we took steps in the design and analytic phases to minimize
bias. To capture potential confounders, we assessed a variety of patient
data, including pharmacy data, microbiology data, and records of
inpatient and outpatient care. To address the impact of confounding by
indication, we utilized propensity score methods in the analytic phase
[20,21,41]. Although balance was achieved within propensity score
quintiles and between propensity matched pairs, there is the potential
for residual confounding by unobserved covariates. Additionally, due
to the relatively small sample size after matching propensity scores, we
may have been unable to detect small differences in clinical outcomes
between the two treatment groups.
Though we sought to develop accurate definitions for exposures,
outcomes, and known potential confounders, misclassification bias
may have impacted our study results. Our definition of suspected
MRSA pneumonia may not have captured all MRSA pneumonia
infections. Previous research has shown that as many as 30% of patients
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never have cultures taken [27]. In addition, we included patients with
positive MRSA respiratory cultures from both sputum and BAL. The
sensitivity of culture-positive isolates from non-bronchoscopic lung
lavage for confirming ventilator-associated pneumonia is reported
to be 72% with a Positive Predictive Value (PPV) of 14%, while the
sensitivity of BAL for confirming pneumonia is 89% with a PPV of
33% [42]. Since our cohort definition for suspected MRSA pneumonia
was based on culture confirmation and the presence of clinical signs
of infection, we performed a subgroup analysis restricting the cohort
to patients with a pneumonia diagnosis code in addition to a positive
culture from a respiratory culture site and clinical signs of infection.
This subgroup analysis demonstrated consistent results with those of
the overall cohort.
Lastly, our study findings were further impacted by the limited
generalizability of the VA population to the general US population.
However, the Veterans Health Administration is the largest integrated
healthcare system in the US. Due to the implementation of electronic
medical records in 1999, large standardized databases, unique in size
and content, include a wealth of information not available from other
national data sources, including barcode medication administration,
microbiology, and lab chemistry data [43].

Conclusions
We evaluated the effectiveness of linezolid therapy compared to
vancomycin in obese patients with culture-confirmed MRSA from
a pulmonary site and found no significant differences in clinical
outcomes between the two treatment groups. In sensitivity analyses,
however, we found that linezolid was associated with a significantly
higher survival rate compared to vancomycin patients with lower
MICs (≤ 1 μg/mL). Based on our review of the literature, this is the first
study to demonstrate improved survival with linezolid as compared to
vancomycin among obese patients with suspected MRSA pneumonia
infected with low vancomycin MICs. As such, further studies are
needed to determine whether this beneficial effect is observed in other
study populations and to determine the clinical implications of this
finding.
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